Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- EquMet Becomes Best Seller for Novartis Japan in FY2018
April 4, 2019
- Japan Pharma Market Skids 1.4% in FY2018: Encise
April 4, 2019
- Gilead’s Biktarvy to Make Japan Debut on April 8
April 4, 2019
- Axcelead Now Independent from Takeda
April 3, 2019
- Kowa Sues Towa over Livalo Generics, Demands 4.5 Billion Yen in Additional Damages
April 3, 2019
- Telomelysin/Keytruda Combo Shows No Dose-Limiting Toxicities in Interim PIa Data: Oncolys
April 3, 2019
- Xospata Significantly Extends OS in PIII Study in FLT3-Mutated AML: Astellas
April 3, 2019
- Sumitomo Dainippon Files Rethio for Conditioning Treatment Prior to HSCT for Malignant Lymphoma
April 3, 2019
- Nichi-Iko Takes Over Futhan from Torii
April 2, 2019
- Nichi-Iko Takes Full Control of Eisai Generic Arm, Now Renamed “Elmed”
April 2, 2019
- Entyvio SC Form Now under EMA Review: Takeda
April 2, 2019
- Chugai Offloading Antiulcer Drug Ulcerlmin to Fuji Chemical
April 2, 2019
- Novel Antibiotic Cefiderocol Accepted for EMA Review: Shionogi
April 2, 2019
- Mundipharma, Maruishi to Copromote Tapenta from June
April 2, 2019
- GSK, Daiichi Sankyo Vaccine Joint Venture Dissolved
April 2, 2019
- Mochida Aims at 108 Billion Yen Sales in FY2021: New 3-Year Biz Plan
April 2, 2019
- Pfizer, Mochida Tie Up for Antidepressant Desvenlafaxine in Japan
April 2, 2019
- Takeda Files Adcetris for PTCL, Pediatric Use in Japan
April 1, 2019
- Daiichi Sankyo Bags US$6.9 Billion AstraZeneca Pact for Cancer Hopeful DS-8201, Announces CEO Change
April 1, 2019
- Safety Monitoring Board Backs PIII Continuation for Elenbecestat: Eisai
April 1, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…